SCHEMBL2486791

SCHEMBL2486791

CCCCCN1C(=O)C(C)(C)c2cc3[nH]c(CNS(=O)(=O)c4cccc(OC)c4)nc3cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
MAPT P10636 3/20 0.41
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
AKT1 P31749 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
CBX7 O95931 1/20 0.36
CDYL2 Q8N8U2 1/20 0.36
CDYL Q9Y232 1/20 0.36
CDY1; CDY1B Q9Y6F8 1/20 0.36
SCN9A Q15858 1/20 0.36
ALDH1A1 P00352 2/20 0.36
DUT P33316 2/20 0.36
MEP1B Q16820 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13341666 0.97 POLB (0.48) POLBMAPTAURKAAURKBAKT1
SCHEMBL2489245 0.83 CBX7 (0.44) MAPTSMN1; SMN2GAACBX7CDYL2
SCHEMBL13341299 0.81 AURKA (0.48) POLBAURKAAURKBSMN1; SMN2CBX7
SCHEMBL13341283 0.80 HDAC1 (0.44) POLBMAPTAURKAAURKBSMN1; SMN2
SCHEMBL13341670 0.80 CBX7 (0.44) MAPTSMN1; SMN2GAACBX7CDYL2
SCHEMBL2490184 0.80 F9 (0.47) MAPTSMN1; SMN2GAACBX7CDYL2
SCHEMBL2492633 0.80 AURKA (0.42) POLBAURKAAURKBSCN9AKMT2A
SCHEMBL2492919 0.79 RAB9A (0.43) AURKAAURKBSMN1; SMN2GAAALDH1A1
SCHEMBL13341410 0.78 AURKA (0.43) MAPTAURKAAURKBSMN1; SMN2GAA
SCHEMBL13341650 0.76 POLB (0.42) POLBAURKAAURKBSCN9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756112-B1 PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS BOEHRINGER INGELHEIM INT (DE) 2011-10-26 EP disclosed
US-7714010-B2 Pyrrolobenzimidazolones and their use as anti-proliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 US disclosed
US-20050261350-A1 Pyrrolobenzimidazolones and their use as anti-proliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 US disclosed
EP-1598353-A1 Pyrrolobenzimidazolones and their use as antiproliferative agents Boehringer Ingelheim International GmbH (DE) 2005-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261350-A1 Pyrrolobenzimidazolones and their use as anti-proliferative agents MKI67, CCNI, CCNA1 POLB 144/4885MAPT 2325/4885AURKA 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.